CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19 CAR-T 细胞治疗肾移植后难治性伯基特淋巴瘤一例
英文原题：CD19 chimeric antigen receptor T-cell therapy for the treatment of a patient with refractory Burkitt lymphoma after kidney transplant.
查看英文原题
CD19 chimeric antigen receptor T-cell therapy for the treatment of a patient with refractory Burkitt lymphoma after kidney transplant.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
本病例表明，在 CAR-T 细胞治疗后使用 CsA 可能是可行的，并提供了初步证据支持将其作为降低移植后淋巴增殖性疾病患者移植物排斥风险的策略进行进一步研究。
研究思路结论见上方概要
背景
CD19 嵌合抗原受体（CAR）T 细胞疗法在治疗移植后淋巴增殖性疾病方面已显示出前景，但移植排斥的风险是公认的，并且对于在 CAR-T 细胞疗法中使用钙调神经磷酸酶抑制剂尚无共识。
方法
我们报告一例难治性Burkitt淋巴瘤的肾移植受者，其在CD19 CAR-T 细胞输注后接受了环孢素A（CsA）治疗。在CsA给药前后进行了连续外周血采样，并通过单细胞RNA测序对样本进行了分析。
结果
患者表现出强劲的CAR-T 细胞扩增并达到完全缓解。体外分析表明，CsA并未显著抑制CAR-T 细胞的激活、扩增或细胞毒性。
展开英文摘要原文
METHODS
We report a kidney transplant recipient with refractory Burkitt lymphoma who received cyclosporine A (CsA) following CD19 CAR T-cell infusion. Serial peripheral blood sampling was performed before and after CsA administration, and samples were analyzed via single-cell RNA sequencing.
RESULTS
The patient exhibited robust CAR T-cell expansion and achieved a complete response. In vitro analyses demonstrated that CsA did not profoundly inhibit CAR T-cell activation, expansion or cytotoxicity.
CONCLUSIONS
This case illustrates that the use of CsA following CAR T-cell therapy may be feasible and provides preliminary evidence supporting its investigation as a strategy for lowering the risk of graft rejection in patients with post-transplant lymphoproliferative disorder.
论文信息
- 作者
- Zhang P、Xu Q、Zhang Z、Zhao L、Huang M、Cai H、Zhu L、Zheng M
- 第一作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
- 通讯作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: miaozheng@tjh.tjmu.edu.cn.China
- 文献类型
- 病例报告
- 期刊
- Cytotherapy2026 May
- 原文标识
- PubMed 41762962 · DOI 10.1016/j.jcyt.2026.102055